DUBLIN--(BUSINESS WIRE)--The "Competitor Analysis: Survivin-Targeted Immunotherapy" report has been added to ResearchAndMarkets.com's offering.
This Competitive Intelligence report analyzes the competitive field of Survivin-Targeted Immunotherapies as of May 2018 in a tabulated format with structured listings of industry-relevant data.
The intracellular protein Survivin is the smallest member of the Inhibitor of apoptosis (IAP) family of proteins, involved in inhibition of apoptosis and regulation of cell cycle. These functional attributes make Survivin an unique protein exhibiting divergent functions i.e. regulating cell proliferation and cell death. Expression pattern of Survivin is also distinctive; it is prominently expressed during embryonal development, absent in most normal, terminally differentiated tissues but upregulated in a variety of human cancers.
Expression of Survivin in tumours correlates with not only inhibition of apoptosis and a decreased rate of cell death, but also resistance to chemotherapy and aggressiveness of tumours. Therefore, Survivin is an important target for cancer vaccines and cellular therapeutics. Survivin peptide sequences have been used to develop vaccination strategies and adoptive cell therapies.
The report includes a compilation of currently active projects in research and development of active immunotherapy and adoptive cell therapy targeting Survivin. In addition, the report lists company- and institution-specific R&D pipelines of Survivin-Targeted Immunotherapies.
Competitor projects are listed in a tabular format providing information on:
- Drug Codes
- Target/Mechanism of Action
- Class of Compound
- Product Category
- R&D Stage
- Additional comments with a hyperlink leading to the source of information.
Key Topics Covered:
1. Survivin-Targeted Immunotherapy
- Survivin-Selective Cancer Vaccines
- Survivin-Specific, Multi-Antigen Cancer Vaccines
- Survivin-Selective Adoptive T-Cell Therapy & Oncolytic Viral Immunotherapy
- Survivin-Specific, Multi-Target Adoptive T-Cell Therapy
2. Corporate Survivin Immunotherapy R&D Pipelines
For more information about this report visit https://www.researchandmarkets.com/research/9j6whl/2018?w=4